These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19952358)

  • 1. Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer.
    Seager CM; Puzio-Kuter AM; Patel T; Jain S; Cordon-Cardo C; Mc Kiernan J; Abate-Shen C
    Cancer Prev Res (Phila); 2009 Dec; 2(12):1008-14. PubMed ID: 19952358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of p53 and Pten promotes invasive bladder cancer.
    Puzio-Kuter AM; Castillo-Martin M; Kinkade CW; Wang X; Shen TH; Matos T; Shen MM; Cordon-Cardo C; Abate-Shen C
    Genes Dev; 2009 Mar; 23(6):675-80. PubMed ID: 19261747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The molecular, the bad, and the ugly: preventing bladder cancer via mTOR inhibition.
    McConkey DJ; Dinney CP
    Cancer Prev Res (Phila); 2009 Dec; 2(12):1001-2. PubMed ID: 19952365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression.
    Delto JC; Kobayashi T; Benson M; McKiernan J; Abate-Shen C
    Oncotarget; 2013 Feb; 4(2):269-76. PubMed ID: 23563166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy.
    Seo HK; Cho KS; Chung J; Joung JY; Park WS; Chung MK; Lee KH
    Urology; 2010 Aug; 76(2):512.e1-7. PubMed ID: 20579709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Downstream Genes of the mTOR Pathway that Predict Recurrence and Progression in Non-Muscle Invasive High-Grade Urothelial Carcinoma of the Bladder.
    Jin S; Chang IH; Kim JW; Whang YM; Kim HJ; Hong SA; Lee TJ
    J Korean Med Sci; 2017 Aug; 32(8):1327-1336. PubMed ID: 28665070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravesical delivery of rapamycin via folate-modified liposomes dispersed in thermo-reversible hydrogel.
    Yoon HY; Chang IH; Goo YT; Kim CH; Kang TH; Kim SY; Lee SJ; Song SH; Whang YM; Choi YW
    Int J Nanomedicine; 2019; 14():6249-6268. PubMed ID: 31496684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy.
    Contreras CM; Akbay EA; Gallardo TD; Haynie JM; Sharma S; Tagao O; Bardeesy N; Takahashi M; Settleman J; Wong KK; Castrillon DH
    Dis Model Mech; 2010; 3(3-4):181-93. PubMed ID: 20142330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment.
    Hung KE; Maricevich MA; Richard LG; Chen WY; Richardson MP; Kunin A; Bronson RT; Mahmood U; Kucherlapati R
    Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1565-70. PubMed ID: 20080688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting mTOR and p53 Signaling Inhibits Muscle Invasive Bladder Cancer In Vivo.
    Madka V; Mohammed A; Li Q; Zhang Y; Biddick L; Patlolla JM; Lightfoot S; Towner RA; Wu XR; Steele VE; Kopelovich L; Rao CV
    Cancer Prev Res (Phila); 2016 Jan; 9(1):53-62. PubMed ID: 26577454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of an orthotopic mouse non-muscle invasive bladder cancer model expressing the mammalian target of rapamycin signaling pathway.
    Kim SJ; Seo HK; Seo HH; Lee SJ; Kwon JK; Lee TJ; Chi BH; Chang IH
    J Korean Med Sci; 2014 Mar; 29(3):343-50. PubMed ID: 24616582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulator of cullins-1 expression knockdown suppresses the malignant progression of muscle-invasive transitional cell carcinoma by regulating mTOR/DEPTOR pathway.
    Wang W; Chen H; Liu Z; Qu P; Lan J; Chen H; Zou L; Qiu J
    Br J Cancer; 2016 Feb; 114(3):305-13. PubMed ID: 26742010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Mouse Models of Bladder Cancer Identify a Prognostic Signature Associated with Risk of Disease Progression.
    Park S; Rong L; Owczarek TB; Bernardo MD; Shoulson RL; Chua CW; Kim JY; Lankarani A; Chakrapani P; Syed T; McKiernan JM; Solit DB; Shen MM; Al-Ahmadie HA; Abate-Shen C
    Cancer Res; 2021 Oct; 81(20):5161-5175. PubMed ID: 34470779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravesical bacillus Calmette-Guérin efficiently reduces p70S6K1 but not 4E-BP1 phosphorylation in nonmuscle invasive bladder cancer.
    Ferrari KL; de Camargo JA; Rocha GZ; Carvalheira JB; Saad MJ; Billis A; Reis LO
    J Urol; 2015 Feb; 193(2):682-9. PubMed ID: 25200808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining Mitomycin C and Regional 70 MHz Hyperthermia in Patients with Nonmuscle Invasive Bladder Cancer: A Pilot Study.
    Geijsen ED; de Reijke TM; Koning CC; Zum Vörde Sive Vörding PJ; de la Rosette JJ; Rasch CR; van Os RM; Crezee J
    J Urol; 2015 Nov; 194(5):1202-8. PubMed ID: 26143111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTOR inhibition suppresses established epilepsy in a mouse model of cortical dysplasia.
    Nguyen LH; Brewster AL; Clark ME; Regnier-Golanov A; Sunnen CN; Patil VV; D'Arcangelo G; Anderson AE
    Epilepsia; 2015 Apr; 56(4):636-46. PubMed ID: 25752454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.
    Wagner AJ; Malinowska-Kolodziej I; Morgan JA; Qin W; Fletcher CD; Vena N; Ligon AH; Antonescu CR; Ramaiya NH; Demetri GD; Kwiatkowski DJ; Maki RG
    J Clin Oncol; 2010 Feb; 28(5):835-40. PubMed ID: 20048174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectivity of intravescical thermo-chemotherapy prophylaxis for patients with high recurrence and progression risk for non-muscle invasive bladder cancer.
    Gözen AS; Umari P; Scheitlin W; Su FE; Akin Y; Rassweiler J
    Arch Ital Urol Androl; 2017 Jun; 89(2):102-105. PubMed ID: 28679178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer.
    Solsona E; Iborra I; Dumont R; Rubio-Briones J; Casanova J; Almenar S
    J Urol; 2000 Sep; 164(3 Pt 1):685-9. PubMed ID: 10953125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mammalian target of rapamycin-dependent acinar cell neoplasia after inactivation of Apc and Pten in the mouse salivary gland: implications for human acinic cell carcinoma.
    Diegel CR; Cho KR; El-Naggar AK; Williams BO; Lindvall C
    Cancer Res; 2010 Nov; 70(22):9143-52. PubMed ID: 21062985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.